DARA BioSciences Sponsors Breast Cancer Awareness Month Segment on
The Balancing Act, airing on Lifetime Television
Oct. 14 and Oct. 21 at 7 a.m. EST
Soltamox® (tamoxifen citrate) is the only oral liquid formulation of tamoxifen available in the US and is an important option for breast cancer patients who have difficulty adhering to tablet therapy.
Tamoxifen is widely used to treat estrogen-receptor positive breast cancer and patients at high risk for the disease. In the US, over 230,000 new cases of breast cancer are diagnosed each year, and over 1.8 million prescriptions are written for tamoxifen.
While tamoxifen is an effective therapy, it must be taken for up to five years in order for the full benefits to be realized. A number of well designed studies indicate long term adherence to treatment is less than optimal, with up to 50% of patients discontinuing treatment earlier than they should. To address the need for improved adherence, Soltamox was developed to offer breast cancer patients a new option for daily compliance. Patients who may benefit from Soltamox include those who prefer a liquid versus a pill, patients who have swallowing difficulties and patients who may benefit from a change in formulation. For patients with intolerance to gluten or lactose, Soltamox is both gluten and lactose free.
Soltamox is available as a sugar-free oral solution (equivalent to 10mg/5mL). Each bottle contains 150 mL.
DARA has an exclusive license to market Soltamox® in the U.S. from Rosemont Pharmaceuticals, LTD, a UK-based manufacturer and marketer of oral liquid medicines. Soltamox is patent-protected through 2018